MA45855B1 - Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide - Google Patents

Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide

Info

Publication number
MA45855B1
MA45855B1 MA45855A MA45855A MA45855B1 MA 45855 B1 MA45855 B1 MA 45855B1 MA 45855 A MA45855 A MA 45855A MA 45855 A MA45855 A MA 45855A MA 45855 B1 MA45855 B1 MA 45855B1
Authority
MA
Morocco
Prior art keywords
bis
new use
isophthalamide
mercaptoethyl
mercaptoethyl isophthalamide
Prior art date
Application number
MA45855A
Other languages
English (en)
French (fr)
Other versions
MA45855A (fr
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of MA45855A publication Critical patent/MA45855A/fr
Publication of MA45855B1 publication Critical patent/MA45855B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA45855A 2016-08-05 2017-08-04 Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide MA45855B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201613535 2016-08-05
PCT/GB2017/052306 WO2018025049A1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Publications (2)

Publication Number Publication Date
MA45855A MA45855A (fr) 2021-03-17
MA45855B1 true MA45855B1 (fr) 2022-02-28

Family

ID=60202272

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45855A MA45855B1 (fr) 2016-08-05 2017-08-04 Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide

Country Status (31)

Country Link
US (2) US20190240173A1 (enExample)
EP (2) EP4029497A1 (enExample)
JP (1) JP6926192B2 (enExample)
KR (1) KR102538388B1 (enExample)
CN (1) CN109562179A (enExample)
AU (1) AU2017305661B2 (enExample)
BR (1) BR112019002130A2 (enExample)
CL (1) CL2019000229A1 (enExample)
CY (1) CY1125039T1 (enExample)
DK (1) DK3493849T3 (enExample)
EA (1) EA201990443A1 (enExample)
ES (1) ES2907838T3 (enExample)
HR (1) HRP20220252T1 (enExample)
HU (1) HUE057782T2 (enExample)
IL (1) IL264538B2 (enExample)
LT (1) LT3493849T (enExample)
MA (1) MA45855B1 (enExample)
MD (1) MD3493849T2 (enExample)
MX (1) MX387853B (enExample)
MY (1) MY199733A (enExample)
NZ (1) NZ750271A (enExample)
PH (1) PH12019500237A1 (enExample)
PL (1) PL3493849T3 (enExample)
PT (1) PT3493849T (enExample)
RS (1) RS62924B1 (enExample)
SG (1) SG11201900565RA (enExample)
SI (1) SI3493849T1 (enExample)
SM (1) SMT202200109T1 (enExample)
UA (1) UA125394C2 (enExample)
WO (1) WO2018025049A1 (enExample)
ZA (1) ZA201900594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
AU2010297933A1 (en) 2009-09-28 2012-04-19 University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands

Also Published As

Publication number Publication date
MA45855A (fr) 2021-03-17
EP4029497A1 (en) 2022-07-20
AU2017305661B2 (en) 2023-05-18
EA201990443A1 (ru) 2019-07-31
CY1125039T1 (el) 2023-03-24
EP3493849A1 (en) 2019-06-12
JP2019524782A (ja) 2019-09-05
PT3493849T (pt) 2022-02-23
ZA201900594B (en) 2019-08-28
RS62924B1 (sr) 2022-03-31
KR20190035724A (ko) 2019-04-03
CA3032858A1 (en) 2018-02-08
LT3493849T (lt) 2022-03-10
MX2019000978A (es) 2019-06-10
KR102538388B1 (ko) 2023-05-30
IL264538B (en) 2022-10-01
US20250325503A1 (en) 2025-10-23
PL3493849T3 (pl) 2022-03-28
US20190240173A1 (en) 2019-08-08
MD3493849T2 (ro) 2022-04-30
CL2019000229A1 (es) 2019-04-26
MX387853B (es) 2025-03-19
MY199733A (en) 2023-11-21
WO2018025049A1 (en) 2018-02-08
SMT202200109T1 (it) 2022-05-12
ES2907838T3 (es) 2022-04-26
HUE057782T2 (hu) 2022-06-28
AU2017305661A1 (en) 2019-02-14
BR112019002130A2 (pt) 2019-05-14
HRP20220252T1 (hr) 2022-04-29
JP6926192B2 (ja) 2021-08-25
IL264538B2 (en) 2023-02-01
EP3493849B1 (en) 2021-12-01
NZ750271A (en) 2025-07-25
UA125394C2 (uk) 2022-03-02
SG11201900565RA (en) 2019-02-27
SI3493849T1 (sl) 2022-04-29
PH12019500237A1 (en) 2019-10-28
CN109562179A (zh) 2019-04-02
IL264538A (enExample) 2019-03-31
DK3493849T3 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
MA48051B1 (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA52948B1 (fr) Composés
CR20220251A (es) Nuevos derivados de metilquinazolinona
MA56553B1 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA39246A1 (fr) Composé hétérocyclique fusionné
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
EA201790271A1 (ru) Ингибиторы гликозидазы
MA39984B1 (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
MA41051B1 (fr) Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MA54386B1 (fr) Modulateurs de trex1
EP3405183A4 (en) ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
CL2020002697A1 (es) Moduladores alostéricos positivos del receptor de dopamina d1
EP3527206A4 (en) Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound
MA39337A1 (fr) Modulateurs de pyrazines de gpr6